This achievement follows the recent confirmation from the Data Safety Review Committee that ISLA-101 has been deemed safe and well-tolerated in the 16 subjects dosed across cohorts 1 and 2, under fasted conditions. The diligent oversight of the Safety Review Committee provides assurance of the drug's safety profile.

In continuation of the study, pending the review of results from cohort 3, the group that received the highest safe dose will undergo final dosing under fed conditions. This strategic approach ensures comprehensive evaluation and optimization of ISLA-101 administration, paving the way for the subsequent phases of clinical trials.

CEO of Island Pharmaceuticals, Dr. David Foster, expressed his satisfaction with the study's progression, stating, "We are very pleased with how this study is progressing and thank all those volunteers participating in it. With the dose now administered to the third cohort, we are moving swiftly toward the completion of dosing for this study. Based on our current progress, we remain on track to read out data in early 2024."

ISLA-101, a well-known drug candidate, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases. The Single Ascending Dose study aims to establish the safety and effectiveness of administered doses in achieving the required blood concentrations to combat the dengue virus. The successful completion of this study will set the stage for Island's planned Phase 2a PEACH clinical trial.

Island Pharmaceuticals remains committed to advancing innovative solutions in antiviral drug development, addressing critical global health challenges. The company anticipates sharing trial data in early 2024, reinforcing its dedication to providing effective and safe solutions for the prevention and treatment of infectious diseases.